PulseAI, a Belfast-based medical technology company developing AI-enabled cardiac diagnostics, has secured a Seed funding round to accelerate clinical and regulatory expansion. The round was led by Innovation Ulster Limited, the commercial venturing arm of Ulster University, with participation from The Mortara Group and The Francis Crick Institute.
Founded in 2019 by Dr. Alan Kennedy, PulseAI builds AI-driven ECG analysis software designed to improve the speed, accuracy, and consistency of cardiac diagnosis across primary and acute care settings. The company said the new capital will be used to scale its AI-ECG platform, pursue U.S. FDA 510(k) clearance, expand clinical validation programs, and deepen enterprise and OEM integrations.
PulseAI’s technology is trained on large-scale ECG datasets and validated with clinical partners across Europe and the United States. Headquartered in Northern Ireland, the company aims to reduce diagnostic variability and broaden access to high-quality cardiac diagnostics across healthcare systems.
